Dosing Schedule and Administration Guide | MenQuadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine)

ADMINISTRATION

Primary Vaccination

• Individuals 2 months old receive MenQuadfi as a 4-dose series at 2, 4, 6, and 12-18 months of age. The first dose may be given as early as 6 weeks¹

• Individuals 6 through 11 months old receive a 2-dose series, with the second dose administered in the second year of life and at least 3 months after the first dose¹

• Individuals 12 through 23 months old receive a 2-dose series, with the second dose administered at least 3 months after the first dose¹

• Individuals 2 years of age and older receive a single dose of MenQuadfi¹

Booster Vaccination

• A single dose of MenQuadfi may be administered to individuals 13 years of age and older who are at continued risk for meningococcal disease if at least 3 years have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine¹

Vaccination Following Prior Dose of Meningococcal Polysaccharide Vaccine

• A single dose of MenQuadfi may be administered if at least 3 years have elapsed since a prior dose of meningococcal polysaccharide vaccine¹

Purchasing considerations

Based on its distinct formulation, MenQuadfi has a unique CPT^® code (90619) for billing purposes.

• MenQuadfi is available through direct purchasing channels and the Vaccines For Children (VFC) program to help keep both publicly and privately insured patients immunized

IMPORTANT SAFETY INFORMATION

MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of MenQuadfi.

Some individuals with altered immunocompetence, including some receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and those receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope (fainting) may occur in association with administration of injectable vaccines, including MenQuadfi. Procedures should be in place to avoid injury from fainting.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following primary vaccination with MenQuadfi in infants 6 weeks through 23 months of age include tenderness, erythema, and swelling at the injection site; irritability, abnormal crying, drowsiness, appetite loss, fever, and vomiting. In individuals 2 years of age and older,the most common adverse reactions include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

to learn more about Sanofi’s commitment to fighting counterfeit drugs.

MenACWY = N meningitidis serogroups A, C, W, and Y. ^*Menveo (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine). ^†Menactra (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine).

MenQuadfi is a registered trademark of Sanofi Inc.

Menactra is a registered trademark of Sanofi, its affiliates, and its subsidiaries.

The other brands listed are trademarks owned by or licensed to their respective owners and are not owned by or licensed to Sanofi, its affiliates and/or its subsidiaries.

REFERENCES:

MenQuadfi [Prescribing Information]. Sanofi Inc.
Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.
Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents aged 13-17 years—National Immunization Survey-Teen, United States, 2021. Centers for Disease Control and Prevention. MMWR Morbid Mortal Week Rep. 2022;71:1101-1108.

With MenQuadfi, you canMAINTAIN THE EXISTING ACIP MenACWY VACCINATION SCHEDULE^1,2

ADMINISTRATION

Presentation

Purchasing considerations

IMPORTANT SAFETY INFORMATION

REFERENCES:

With MenQuadfi, you canMAINTAIN THE EXISTING ACIP MenACWY VACCINATION SCHEDULE1,2

ADMINISTRATION

Presentation

Purchasing considerations

IMPORTANT SAFETY INFORMATION

REFERENCES:

With MenQuadfi, you canMAINTAIN THE EXISTING ACIP MenACWY VACCINATION SCHEDULE^1,2